Explosive advances in healthcare technology are creating “technology M&A” opportunities leading to new patient-outcome focused pharmaceutical business models. Digital is a crucial vehicle to create healthcare technology-enabled services that enhance the value of products and improve patient care. With deal activity between biopharmaceutical and medical device organizations at an all-time high—the race is on to reshape product portfolios and place bets on new technology to position for growth and innovation.
Life sciences companies need to redefine their role in the new healthcare ecosystem, going “beyond pills and apps.” Providing a combination of products and embedded services to augment market position and deliver improved patient outcomes is not traditionally a core pharmaceutical skill set. Yet pharmaceutical, biotech and medical device companies are well poised to participate in this transformation since they have the ability to go beyond just offering products to offering solutions to the largest healthcare cost-contributors, including cancer, diabetes, heart failure, COPD and neurologic disorders.
Download the PDF [PDF, 843KB]